Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TRVI Trevi Therapeutics, Inc.

Market Closed 12-19 16:00:00 EST

13.01

+0.82

+6.73%

盘后13.15

+0.14+1.08%

19:53 EST

High13.22	Low12.28	Vol3.65M
Open12.48	D1 Closing12.19	Amplitude7.71%
Mkt Cap1.67B	Tradable Cap1.26B	Total Shares128.23M
T/O47.08M	T/O Rate3.76%	Tradable Shares97.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TRVI","market":"US","secType":"STK","nameCN":"Trevi Therapeutics, Inc.","latestPrice":13.01,"timestamp":1766178000000,"preClose":12.19,"halted":0,"volume":3653770,"hourTrading":{"tag":"盘后","latestPrice":13.15,"preClose":13.01,"latestTime":"19:53 EST","volume":912928,"amount":11877271.698,"timestamp":1766192033447},"delay":0,"floatShares":97087500,"shares":128230134,"eps":-0.367299,"marketStatus":"Market Closed","change":0.82,"latestTime":"12-19 16:00:00 EST","open":12.48,"high":13.22,"low":12.28,"amount":47079301.4401,"amplitude":0.077112,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.367299,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1557201600000,"exchange":"NASDAQ","adjPreClose":12.19,"preHourTrading":{"tag":"盘前","latestPrice":12.5,"preClose":12.19,"latestTime":"09:29 EST","volume":7337,"amount":90011.658671,"timestamp":1766154599999},"postHourTrading":{"tag":"盘后","latestPrice":13.15,"preClose":13.01,"latestTime":"19:53 EST","volume":912928,"amount":11877271.698,"timestamp":1766192033447},"volumeRatio":1.7827247682475276,"impliedVol":0.6654,"impliedVolPercentile":0.392},"requestUrl":"/m/hq/s/TRVI","defaultTab":"news","newsList":[{"id":"2592194817","title":"Trevi Therapeutics (TRVI): Evaluating Valuation After Appointing Veteran Biopharma CFO David Hastings","url":"https://stock-news.laohu8.com/highlight/detail?id=2592194817","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592194817?lang=en_us&edition=fundamental","pubTime":"2025-12-20 01:12","pubTimestamp":1766164367,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI) just named veteran finance executive David Hastings as its next Chief Financial Officer, effective January 6, 2026, a move that immediately sharpened investor focus on the stock’s trajectory.\nSee our latest analysis for Trevi Therapeutics.\nThe timing of Hastings’ appointment coincides with Trevi’s 90-day share price return of nearly 50 percent and roughly 180 percent year-to-date share price gain, which together indicate firmly building momentum, supported by a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/trevi-therapeutics-trvi-evaluating-valuation-after-appointin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/trevi-therapeutics-trvi-evaluating-valuation-after-appointin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TRVI","BK4007"],"gpt_icon":0},{"id":"2589818815","title":"Trevi Therapeutics Sets $522,000 Salary and Bonus Package for New CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818815","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818815?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:58","pubTimestamp":1764943119,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Inc. has announced the appointment of David Hastings as Chief Financial Officer and principal financial officer, effective January 6, 2026. Under the terms of his offer letter, Hastings will receive an annualized base salary of $522,000 and will be eligible for an annual incentive bonus of up to 40% of his base salary. In addition, upon commencing employment, he will be granted an option to purchase 375,000 shares of the company's common stock at the closing price on the date of grant. The stock option will vest 25% after one year, with the remainder vesting in equal monthly installments over the following three years. Hastings will also be eligible for separation benefits under the company's Executive Separation Benefits and Retention Plan.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL7ZKdtS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"gpt_icon":0},{"id":"2588844298","title":"Trevi Therapeutics Names David Hastings CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2588844298","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588844298?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853231,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI) said Thursday it has appointed David Hastings as its chief financial officer, effective Jan. 6, 2026.Hastings was previously Arbutus BioPharma's (ABUS) CFO, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TRVI","BK4007","ABUS","LENZ","BK4539"],"gpt_icon":0},{"id":"2588881946","title":"Trevi Therapeutics Names David Hastings as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881946","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881946?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:30","pubTimestamp":1764851448,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Inc. has appointed David Hastings as Chief Financial Officer, effective January 6, 2026. Hastings brings over 25 years of experience in financial leadership roles within the life sciences and biopharmaceutical sectors, including previous CFO positions at Arbutus, Unilife, Incyte, and ArQule.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on December 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9HX2Vv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069347547.HKD","LU2461242641.AUD","IE00BN8TJ469.HKD","LU1162221912.USD","LU1917777945.USD","LU0211331839.USD","BK4559","IE00BLSP4452.SGD","SG9999015358.SGD","LU0266013472.USD","BK4588","LU0965509101.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU1941712264.USD","SG9999002232.USD","LU1116320737.USD","LU1430594728.SGD","LU2023250843.SGD","LU1061106388.HKD","LU1983299246.USD","LU2106854487.HKD","IE00BSNM7G36.USD","IE0009355771.USD","LU1035773651.USD","BK4550","LU0203345920.USD","LU1291159041.SGD","LU1066051225.USD","LU2324357040.USD","LU0203347892.USD","SG9999001176.SGD","LU1934455194.USD","MRK","SG9999014559.SGD","LU0320765489.SGD","LU1941712348.USD","IE00BJJMRZ35.SGD","IE00BBT3K403.USD","LU1585245621.USD","LU0098860793.USD","LU1116320901.HKD","INCY","BK4585","LU0106261372.USD","LU0122379950.USD","SG9999013999.USD","TRVI","IE00B1BXHZ80.USD","SG9999014567.USD"],"gpt_icon":0},{"id":"2588881546","title":"Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881546","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881546?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:30","pubTimestamp":1764851400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUABZNWD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"2588688195","title":"Trevi Therapeutics Inc - David Hastings to Assume CFO Role on January 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588688195","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588688195?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:30","pubTimestamp":1764851400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUABZNWD7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"2586549242","title":"The Bull Case For Trevi Therapeutics (TRVI) Could Change Following Narrowed Losses and New Shelf Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2586549242","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586549242?lang=en_us&edition=fundamental","pubTime":"2025-11-25 02:12","pubTimestamp":1764007972,"startTime":"0","endTime":"0","summary":"On November 13, 2025, Trevi Therapeutics, Inc. announced third quarter earnings, reporting a reduced net loss of US$11.8 million and basic loss per share of US$0.08 compared to the previous year, alongside a new shelf registration filing allowing issuance of various securities in the future.\nThis combination of narrowing quarterly losses and a fresh shelf registration presents investors with insights into both current financial performance and future fundraising flexibility.\nWe'll explore...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/the-bull-case-for-trevi-therapeutics-trvi-could-change-follo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/the-bull-case-for-trevi-therapeutics-trvi-could-change-follo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"2585170092","title":"Trevi Therapeutics (TRVI): Evaluating Valuation Following Narrowed Loss and Financial Flexibility Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2585170092","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585170092?lang=en_us&edition=fundamental","pubTime":"2025-11-23 00:21","pubTimestamp":1763828505,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI) grabbed investor attention after reporting third quarter results showing its net loss narrowed compared to last year. The company also moved to file a universal shelf registration, providing added financial flexibility.\nSee our latest analysis for Trevi Therapeutics.\nThe buzz around Trevi Therapeutics isn’t just about earnings; the stock has seen its share price leap by 152% year-to-date, with the one-year total shareholder return soaring an even more impressive...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/trevi-therapeutics-trvi-evaluating-valuation-following-narro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/trevi-therapeutics-trvi-evaluating-valuation-following-narro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TRVI","BK4007"],"gpt_icon":0},{"id":"2584221069","title":"Trevi Therapeutics Q3 Net Income USD -11.802 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584221069","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584221069?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:40","pubTimestamp":1763574030,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Trevi Therapeutics Q3 operating expenses USD 13.916 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202521:01:00.03 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD5MnLDc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"gpt_icon":0},{"id":"1172828492","title":"Stock Track | Trevi Therapeutics Soars 5.93% as Multiple Analysts Reaffirm Buy Ratings and Raise Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1172828492","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172828492?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:32","pubTimestamp":1763130753,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics, Inc. (TRVI) shares surged 5.93% in pre-market trading on Friday, following a series of bullish analyst reports that reaffirmed Buy ratings and raised price targets for the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TRVI"],"gpt_icon":0},{"id":"2583104504","title":"Trevi Therapeutics, Inc. : Oppenheimer Raises Target Price to $24 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2583104504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583104504?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:20","pubTimestamp":1763130045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nAZN4QSJJR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRVI","BK4007"],"gpt_icon":0},{"id":"2583501363","title":"Trevi Therapeutics (TRVI) Gets a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2583501363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583501363?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:36","pubTimestamp":1763127392,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Trevi Therapeutics today and set a price target of $25.00. According to TipRan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/trevi-therapeutics-trvi-gets-a-buy-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/trevi-therapeutics-trvi-gets-a-buy-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRVI","BK4007"],"gpt_icon":0},{"id":"2583570571","title":"Trevi Therapeutics (TRVI) Receives a Buy from Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2583570571","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583570571?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:17","pubTimestamp":1763119029,"startTime":"0","endTime":"0","summary":"In a report released today, Kaveri Pohlman from Clear Street maintained a Buy rating on Trevi Therapeutics, with a price target of $21.00. Pohlman ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/trevi-therapeutics-trvi-receives-a-buy-from-clear-street-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/trevi-therapeutics-trvi-receives-a-buy-from-clear-street-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"1190887669","title":"Stock Track | Trevi Therapeutics Plunges 5.76% After-Hours on Q3 Loss and $200M Stock Offering Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1190887669","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190887669?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:26","pubTimestamp":1763072792,"startTime":"0","endTime":"0","summary":"Shares of Trevi Therapeutics, Inc. (TRVI) tumbled 5.76% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and the announcement of a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TRVI"],"gpt_icon":0},{"id":"1197120831","title":"Stock Track | Trevi Therapeutics Plunges 5.76% After Hours on Q3 Results and $200 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=1197120831","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197120831?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:26","pubTimestamp":1763072790,"startTime":"0","endTime":"0","summary":"Shares of Trevi Therapeutics, Inc. (TRVI) experienced a sharp 5.76% decline in after-hours trading on Thursday, following the release of the company's third-quarter 2025 financial results and the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TRVI"],"gpt_icon":0},{"id":"2583510153","title":"Trevi Therapeutics Inc Says in Addition, Offering of up to $200 Mln of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2583510153","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583510153?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:14","pubTimestamp":1763072045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP2BX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"2583101325","title":"Trevi Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed  - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583101325","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583101325?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:14","pubTimestamp":1763072045,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP2BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRVI","BK4007"],"gpt_icon":0},{"id":"1173408137","title":"Stock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1173408137","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173408137?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:08","pubTimestamp":1763068113,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics, Inc. (NASDAQ: TRVI) saw its stock price plummet by 5.57% during Thursday's intraday trading session following the release of its third-quarter 2025 financial results. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TRVI"],"gpt_icon":0},{"id":"1152590401","title":"Stock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1152590401","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152590401?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:08","pubTimestamp":1763068112,"startTime":"0","endTime":"0","summary":"Shares of Trevi Therapeutics, Inc. (TRVI) plunged 5.57% in intraday trading following the release of the company's third-quarter 2025 financial results. The biopharmaceutical firm, which focuses on...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TRVI"],"gpt_icon":0},{"id":"2583148945","title":"Earnings Flash (TRVI) Trevi Therapeutics Posts Q3 Loss Per Share $0.08, vs. FactSet Est of $0.10 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2583148945","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583148945?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:07","pubTimestamp":1763068067,"startTime":"0","endTime":"0","summary":"Earnings Flash (TRVI) Trevi Therapeutics Posts Q3 Loss Per Share $0.08, vs. FactSet Est of $0.10 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TRVI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trevitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.1784},{"period":"3month","weight":0.5963},{"period":"6month","weight":1.1829},{"period":"1year","weight":2.1349},{"period":"ytd","weight":2.1578}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.099656},{"month":2,"riseRate":0.833333,"avgChangeRate":0.203564},{"month":3,"riseRate":0.5,"avgChangeRate":0.396594},{"month":4,"riseRate":0.5,"avgChangeRate":0.125322},{"month":5,"riseRate":0,"avgChangeRate":-0.128619},{"month":6,"riseRate":0.714286,"avgChangeRate":0.210852},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.013323},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.078417},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065787},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.063981},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.046063},{"month":12,"riseRate":0.571429,"avgChangeRate":0.039978}],"exchange":"NASDAQ","name":"Trevi Therapeutics, Inc.","nameEN":"Trevi Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Trevi Therapeutics, Inc.(TRVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Trevi Therapeutics, Inc.,TRVI,Trevi Therapeutics, Inc.股票,Trevi Therapeutics, Inc.股票老虎,Trevi Therapeutics, Inc.股票老虎国际,Trevi Therapeutics, Inc.行情,Trevi Therapeutics, Inc.股票行情,Trevi Therapeutics, Inc.股价,Trevi Therapeutics, Inc.股市,Trevi Therapeutics, Inc.股票价格,Trevi Therapeutics, Inc.股票交易,Trevi Therapeutics, Inc.股票购买,Trevi Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Trevi Therapeutics, Inc.(TRVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction